Express News | Mersana Therapeutics Inc : Guggenheim Cuts Target Price to $5 From $7

Breakings19:36

Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility

TipRanksJan 11 23:26 · Ratings

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaJan 11 05:06

Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating

MT NewswiresJan 11 02:01 · Ratings

LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8

Futu NewsJan 10 23:31 · Ratings

Mersana Therapeutics Shares Are Trading Lower. The Company Announced Initial Clinical Data From the Phase 1 Dose Escalation and Backfill Cohorts for Emiltatug Ledadotin.

BenzingaJan 10 22:03